The Center for Research in Inflammatory Diseases (CRID) was created with the aim of producing integrative and translational scientific research to identify and validate new biological pathways involved in the induction and resolution of inflammation. To this end, it counts on the experience of researchers from various fields of Biomedical Sciences linked to basic research (genetics, molecular and cell biology, immunology, pharmacology, and pathology) and clinical research (rheumatology, immunology, infectology, and dermatology), in addition to researchers in the area of bioinformatics.
Inflammatory diseases constitute a complex and heterogeneous group of diseases that affect more than 10% of the world population. The treatment alternatives currently available are limited and, in some cases, ineffective, considering that information on the underlying mechanisms of the inflammatory process and the pathophysiology of inflammatory diseases is still lacking.
The specific objective of the Center is to advance knowledge about inflammatory diseases (infectious, autoimmune, and related to the cardiovascular system) to recognize and understand the molecular, immunological, pathological, and pharmacological mechanisms involved; identify new biological targets for the development of pharmacological therapeutic tools; search for possible diagnostic markers and prognostic indications, and apply new knowledge to design and synthesize molecules aimed at treating inflammatory diseases.
Benefits were observed in a clinical trial involving 38 volunteers treated at the teaching hospital of the University of São Paulo’s Ribeirão Preto Medical School. The drug is cheap and can shorten ICU stays but should not be used outside hospitals, the researchers warn.
Researchers have correlated information on drugs, genes and diseases to identify potential candidates for psychiatric and neurological treatment. The methodology they developed will be used to search for drugs against COVID-19.
Selected projects aim to repurpose existing drugs for treatment of COVID-19, find novel compounds with therapeutic potential and develop alternative diagnostic methods. The call remains open until June 22.
Metabolic changes associated with diseases such as pulmonary hypertension and chronic obstructive pulmonary disease may reprogram gene expression to increase production of a protein used by SARS-CoV-2 to penetrate lung cells.
Partnering with scientists at Harvard, a group of Brazilians affiliated with the Center for Research on Inflammatory Diseases (CRID), supported by FAPESP, described the mechanisms that cause hair color loss in extreme situations.
A Brazilian team at FAPESP-supported Center for Research on Inflammatory Diseases identified the strategy used by immune cells to combat the pathogen Mayaro virus, which causes symptoms similar to those of chikungunya fever. These results pave the way for the development of drugs.
Phylogenomic analysis shows that pathogen isolated in Brazilian hospital does not belong to the genus Leishmania. Researchers are investigating whether this species alone can cause severe disease or intensifies symptoms in co-infected patients.